替西木单抗联合度伐利尤单抗治疗不可切除肝细胞癌的安全性、疗效与药效学:I/II期研究随机扩展
这项I/II期随机扩展研究评估了替西木单抗与度伐利尤单抗单药及联合方案(含单次启动剂量T300+D)治疗索拉非尼进展/不耐受/拒绝的不可切除肝细胞癌患者,主要终点为安全性。332例患者随机分组,各方案耐受性可接受,T300+D组客观缓解率24.0%、中位总生存18.7个月,获益-风险特征最有利。
要点
- T300+D组3级及以上治疗相关不良事件发生率37.8%,耐受性可接受。
- T300+D组确认客观缓解率24.0%(95%CI 14.9-35.3),高于其他单药或联合组。
- T300+D组中位总生存18.7个月(95%CI 10.8-27.3),各方案中最高。
核心结论
- 所有方案均耐受且具有临床活性,但T300+D方案的获益-风险特征最令人鼓舞。
- T300+D独特的药效学活性及其与客观缓解率的关联支持其在肝细胞癌中继续评估。
研究设计与样本
- I/II期随机扩展研究,纳入332例不可切除肝细胞癌患者(T300+D组75例,度伐利尤单抗组104例,替西木单抗组69例,T75+D组84例)。
- 患者为索拉非尼治疗进展、不耐受或拒绝者,随机分配至T300+D、度伐利尤单抗单药、替西木单抗单药或T75+D方案。
- 主要终点为安全性,次要终点包括RECIST v1.1客观缓解率和总生存,探索性终点包括循环淋巴细胞谱。
主要发现
- 3级及以上治疗相关不良事件发生率在T300+D、度伐利尤单抗、替西木单抗和T75+D组分别为37.8%、20.8%、43.5%和24.4%。
- 确认客观缓解率(95%CI)分别为24.0%(14.9-35.3)、10.6%(5.4-18.1)、7.2%(2.4-16.1)和9.5%(4.2-17.9)。
- 中位总生存(95%CI)分别为18.7(10.8-27.3)、13.6(8.7-17.6)、15.1(11.3-20.5)和11.3(8.4-15.0)个月。
- 各治疗组中CD8+淋巴细胞的早期扩增与缓解相关,T300+D组增殖性CD8+淋巴细胞水平最高。
临床怎么用
- 对于索拉非尼治疗失败或不耐受的不可切除肝细胞癌患者,T300+D方案可作为后续治疗选择之一。
- 治疗期间需监测治疗相关不良事件,T300+D组3级及以上发生率为37.8%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring a single, priming dose of tremelimumab (ClinicalTrials.gov identifier: NCT02519348). PATIENTS AND METHODS: Patients with HCC who had progressed on, were intolerant to, or refused sorafenib were randomly assigned to receive T300 + D (tremelimumab 300 mg plus durvalumab 1,500 mg [one dose each during the first cycle] followed by durvalumab 1,500 mg once every 4 weeks), durvalumab monotherapy (1,500 mg once every 4 weeks), tremelimumab monotherapy (750 mg once every 4 weeks [seven doses] and then once every 12 weeks), or T75 + D (tremelimumab 75 mg once every 4 weeks plus durvalumab 1,500 mg once every 4 weeks [four doses] followed by durvalumab 1,500 mg once every 4 weeks). Safety was the primary end point. Secondary end points included objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors v1.1 and overall survival; exploratory end points included circulating lymphocyte profiles. RESULTS: A total of 332 patients were enrolled (T300 + D, n = 75; durvalumab, n = 104; tremelimumab, n = 69; and T75 + D, n = 84). Tolerability was acceptable across arms, with grade ≥ 3 treatment-related adverse events occurring in 37.8%, 20.8%, 43.5%, and 24.4%, respectively. Confirmed ORRs (95% CI) were 24.0% (14.9 to 35.3), 10.6% (5.4 to 18.1), 7.2% (2.4 to 16.1), and 9.5% (4.2 to 17.9), respectively. An early expansion of CD8+ lymphocytes was associated with response across arms, with highest proliferating CD8+ lymphocyte levels occurring in the T300 + D arm. The median (95% CI) overall survival was 18.7 (10.8 to 27.3), 13.6 (8.7 to 17.6), 15.1 (11.3 to 20.5), and 11.3 (8.4 to 15.0) months in the T300 + D, durvalumab, tremelimumab, and T75 + D arms, respectively. CONCLUSION: All regimens were found to be tolerable and clinically active; however, the T300 + D regimen demonstrated the most encouraging benefit-risk profile. The unique pharmacodynamic activity and association with ORR of the T300 + D regimen further support its continued evaluation in HCC.
引用
- Kelley RK, Sangro B, Harris W, et al. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. J Clin Oncol. 2021. PMID: 34292792. doi:10.1200/JCO.20.03555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。